These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 9167749

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.
    Schiller JH, Storer B, Arzoomanian R, Tutsch K, Alberti D, Spriggs D.
    Invest New Drugs; 1993 Nov; 11(4):291-300. PubMed ID: 8157471
    [Abstract] [Full Text] [Related]

  • 23. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
    Stöger H, Samonigg H, Krainer M, Ploszczynski M, Nirnberger G, Maca S, Hehenwarter W, Wirth M, Schüller J, Vavra N, Scheithauer W, Kornek G, Stierer M, Zielinski CC.
    Eur J Cancer; 1998 Mar; 34(4):482-8. PubMed ID: 9713297
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
    Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward DM, Miller L, Christian M, Taetle R.
    J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL, Douillard JY, Rivière A, Quoix E, Lagrange JL, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T.
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [Abstract] [Full Text] [Related]

  • 32. GM-CSF, carboplatin, doxorubicin: a phase I study.
    Poplin EA, Alberts DS, Rinehart JJ, Smith HO, Neidhart JA, Hersh EM.
    Cancer Chemother Pharmacol; 1994 May; 33(4):340-6. PubMed ID: 8281628
    [Abstract] [Full Text] [Related]

  • 33. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
    Gill PS, Bernstein-Singer M, Espina BM, Rarick M, Magy F, Montgomery T, Berry MS, Levine A.
    AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
    [Abstract] [Full Text] [Related]

  • 34. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG.
    Cancer Res; 1993 Dec 15; 53(24):5929-33. PubMed ID: 8261405
    [Abstract] [Full Text] [Related]

  • 35. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 15; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M.
    J Clin Oncol; 1997 Jul 15; 15(7):2510-7. PubMed ID: 9215819
    [Abstract] [Full Text] [Related]

  • 38. A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.
    Fernandez MC, Krailo MD, Gerbing RR, Matthay KK.
    Cancer; 2000 Jun 15; 88(12):2838-44. PubMed ID: 10870069
    [Abstract] [Full Text] [Related]

  • 39. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF, Chan HO.
    Pharmacotherapy; 2005 Mar 15; 25(3):372-8. PubMed ID: 15843284
    [Abstract] [Full Text] [Related]

  • 40. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J.
    J Clin Oncol; 1998 Feb 15; 16(2):642-50. PubMed ID: 9469353
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.